Physicians’ and Pharmacists’ Perception and Practice of Hospital Pharmacist’ Professional Role in Egypt

مايو 06, 2020

Amira Shaaban Nadia Hussain

مستويات أشكال فيتامين (د) وفيتامين (د) أشكال الجينات في البالغين: نتائج عمال الزراعة في البنجاب ، باكستان

يناير 09, 2020

Nadia Hussain Amira SA Said Mirza Rafi Baig

Influence of Health Literacy on Medication Adherence Among Elderly Females With Type 2 Diabetes in Pakistan

يناير 01, 2020

Nadia Hussain Amira Shaaban Zainab Khan

Mindfulness-Based Meditation Versus Progressive Relaxation Meditation: Impact on Chronic Pain in Older Female Patients With Diabetic Neuropathy

نوفمبر 07, 2019

Nadia Hussain Amira Shaaban Mirza Baig

الدلالة السريرية للعقاقير المخفضة للكوليسترول - تفاعل الماكروليدات: مراجعة شاملة للحياة ، تقارير الحالة والدراسات السكانية ، العلاجات وإدارة المخاطر السريرية

أغسطس 30, 2019

• Abu Mellal A Hussain N Said ASA

Effects of Alogliptin on hypertensive chronic kidney disease with Type 2 diabetes mellitus

مايو 03, 2018

Amira Shaaban Nadia Hussain Farideh Javaid

Background: Diabetes mellitus(DM)is a leading cause of chronic kidney disease (CKD). Theantihyperglycemic treatment options for patients with Type 2 DM are limited because of safety and tolerability concerns. Aims: To retrospectively assess the effect of using Alogliptin; a dipeptidyl peptidase-4 inhibitor (DPP-4i) alongwith conventional gliclazide: a sulphonylurea (SU) on renal outcomes and glycaemiccontrol in T2DM patients with mildCKDand hypertension. Methods: A total of 76 patient records (38 males and 38 females) of patient ages 40–60 were analysed from the kidney unit at Punjab Care hospital, Lahore, Pakistan. All patients had a confirmed history of T2DM with mild CKD and established hypertension.Eligible patients were divided into two groups of 38 individuals each. Group SU received gliclazide monotherapy (SU) or Alogliptin (DPP-4i)+gliclazide (SU) add on therapy. All patients were followed up for 12 months.ResultsThe alogliptin (DPP-4i) plus gliclazide (SU) add on therapy group, in comparison to the group only receiving gliclazide (SU), showed a significant difference in eGFR values. The mean±SD GFR values post 12 months were 74.8±0.31(95%CI:74.8±0.09;74.7–74.9) and 76.1±0.25(95%CI: 76.1±0.08;76.0-76.2) for SU vs.SU+DPP-4i, respectively, with mean calculated effect size of 1.6,.HbA1c, 1,5 AG and ipid profile values have significantly changed(p<0.05) while blood pressure values showed no change. The mean±SD systolic blood pressure readings post 12 months for for SU vs.SU+DPP-4i were 131.4±10.4 (95% CI 131.4±3.3;128.1–134.7), and 131.8±9.9 (95%CI 131.8±3; 128.8–134.8), respectively. Conclusion: In the present study, patients using alogliptin in addition to sulfonyl urea showed improved glycaemic control and lipid profile without increased occurrence of hypoglycaemia. We concluded that, DPP-4iinhibitors are safe treatment options for patients with type 2 diabetes and mild degree of renal impairment.

Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

أبريل 19, 2018

Nadia Hussain Amira Shaaban Zainab Khan

Abstract Aim. To evaluate the safety issues and adverse effects of using TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) versus TCP regimen (docetaxel, carboplatin, and trastuzumab) in older postmenopausal women with nonmetastatic HER2-positive breast cancer. HER2 overexpressed in 20–25% of breast cancer signals an aggressive form of breast cancer and is treated with trastuzumab and pertuzumab. Methods. The patient record database was accessed to identify all postmenopausal women in the Punjab Care hospital who were above 65 years old, with stages 1–3 HER2-positive breast cancer and treated with neoadjuvant TCHP and neoadjuvant TCP from 2013 till 2016. Results. In TCH-P group and TCH group, mild fatigue (34% versus 36%) and diarrhea (48% versus 49%) were most common toxicities. Fever in TCH-P group and TCH group (12% versus 13%) was common. Anorexia affected 21% and 16% of patients receiving TCH and TCHP regimen, respectively. Febrile neutropenia was higher in TCH-P group 13% (3/23) versus 4.5% (1/22) in TCH group. Also 27.2% (6/22) of TCH-P group was hospitalized for treatment related toxicities versus 21.7% (5/23) of TCH group. Conclusion. Comparing neoadjuvant TCP and neoadjuvant TCH-P showed TCH-P regimen had an acceptable toxicity profile. Severe cardiac dysfunction was not observed. Using TCH-P regimen can be considered as relatively safe therapeutic option for elderly postmenopausal women with nonmetastatic HER2-positive breast cancer.

Knowledge, attitude, and practice analysis of corticosteroid use among patients: A study based in the United Arab Emirates

فبراير 09, 2017

Amira Shaaban Amina Mahdy Nadia Hussain Doaa Khalidi

Background: Corticosteroids (CS) have long been known as the most powerful of all known anti-inflammatory agents. Since their introduction in 1949, they have shown pivotal role in the treatment of various serious disorders such as autoimmune diseases, allergic processes, organ transplantation, rheumatologic, dermatological, pulmonary, hematological, ophthalmologic, gastrointestinal disorders, and others. Nevertheless, such massive clinical use does not come without risks, where prolonged use has been linked to several serious side effects. Therefore, careful consideration of precautions recommended for safe use of CS is of paramount importance. Aims and Objectives: To assess knowledge, attitude, and practice (KAP) analysis of the proper use of different dosage forms of CS medications in different sets of CS users in the United Arab Emirates (UAE), to explore the extent to which steroid outpatients were well engaged with medication proper use and safety-related behaviors. Materials and Methods: A structured interview-based methodology was adopted to assess the KAPs revolving around steroid usage in patients located in the UAE cities; Dubai, Sharjah, Ajman and Al Ain. Patients (n = 250) were selected randomly from different outpatient clinics all over the previously designated cities. The prepared interview questions were selected based on related therapeutics guidelines regarding aspects of proper patients CS use. Data were collected by well-trained researchers to conduct such interviews. SPSS V16.0 (SPSS Inc., Chicago, USA) was used for data analysis. Standard descriptive and analytical statistics were used to analyze the data. StudentÂ’s t-test was used to compare the mean difference of continuous variables. Results: Overall, our study showed poor KAP results among different UAE patients using different CS dosage forms. Conclusion: Despite the massive use of CS in almost every clinical settings and its inherent associated risks, patients still needs provisions for better education regarding their medication efficacy, safety, and proper use. By careful follow-up of proper CS use instructions, both patients and physicians would positively reach an optimized cost-effective therapeutic approach with much more improved benefit/risk ratio.